Funding

AirNexis Therapeutics

United States · Biotech

AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.

Visit airnexis.comFunding history

Product and customer workflow

AN01 is a dual PDE3/4 inhibitor being studied as inhaled suspension and powder formulations. Licensed from Haisco, the candidate was in Phase 2 studies in China at the company’s launch. AirNexis is responsible for development in its licensed territories; Haisco retains specified Greater China rights.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$200MEnavate Sciences — Role not disclosedFrazier Life Sciences — Role not disclosedLife Sciences at Goldman Sachs Alternatives — Role not disclosedLongitude Capital — Role not disclosedOrbiMed — Role not disclosedSR One — Role not disclosed

Investors

Enavate SciencesSeries AFrazier Life SciencesSeries ALife Sciences at Goldman Sachs AlternativesSeries ALongitude CapitalSeries AOrbiMedSeries ASR OneSeries A

Coverage

Jan 9, 2026AirNexis Therapeutics · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesbusinesswire.com ↗